QPPV.COM KNOWLEDGE ASSESSMENT

eDISH: Evaluating Drug-Induced Serious Hepatotoxicity in Clinical Trials

Test your understanding of the concepts covered by eDISH: Evaluating Drug-Induced Serious Hepatotoxicity in Clinical Trials.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why are liver-test values commonly expressed as multiples of ULN in eDISH analyses?

To eliminate all effects of baseline liver disease To make results from laboratories with different reference ranges more comparable To determine whether an abnormality is definitely treatment-related To ensure that all values follow a normal statistical distribution

Question 2 of 10 Why is counting the number of upper-right eDISH subjects insufficient for assessing a drug-level signal?

The upper-right region is unrelated to liver safety Each subject requires medical review, and the denominator, exposure, control findings, and alternative causes affect interpretation Only subjects with normal baseline tests should be counted, regardless of treatment A single confirmed case is always equivalent to ten unreviewed outliers

Question 3 of 10 What is the main significance of the lower-right Temple's Corollary region?

It identifies bilirubin elevation without aminotransferase elevation It identifies substantial aminotransferase elevation without substantial bilirubin elevation It confirms cholestatic drug-induced liver injury It demonstrates that the investigational product is unrelated to liver-test abnormalities

Question 4 of 10 Why can use of independently determined maximum ALT and bilirubin values be misleading?

The values may have been measured using different units only The two maxima may have occurred at different times and therefore may not represent a concurrent pattern Maximum values cannot be expressed relative to ULN Independent maxima always underestimate the severity of liver injury

Question 5 of 10 What is the primary purpose of an eDISH analysis in a clinical trial?

To diagnose drug-induced liver injury in individual subjects To visualise liver-test patterns and identify subjects requiring further medical review To calculate the probability that the investigational product caused liver injury To replace clinical narratives with an automated liver-safety classification

Question 6 of 10 Why should deliberate rechallenge generally not be undertaken solely to establish a pharmacovigilance diagnosis?

Rechallenge is prohibited because liver tests cannot be measured afterward Recurrence may provide evidence but can expose the subject to clinically significant risk Rechallenge has no possible value in causality assessment Rechallenge is required before any DILI case can be classified

Question 7 of 10 Why does the absence of a dose relationship not exclude drug-induced liver injury?

Idiosyncratic DILI may occur without a predictable dose-response pattern Dose relationships are never relevant to liver safety A dose relationship can only be assessed after marketing DILI is defined as an abnormality occurring at every dose

Question 8 of 10 A subject is in the upper-left region of a traditional eDISH plot. Which interpretation is most appropriate?

The subject has the classical Hy's Law laboratory pattern The subject has aminotransferase elevation without bilirubin elevation The subject has bilirubin elevation without substantial aminotransferase elevation and requires evaluation for several possible causes The subject can be excluded from liver-safety review because the aminotransferases are not markedly elevated

Question 9 of 10 Which statement best describes the relationship between eDISH and Hy's Law?

They are interchangeable names for the same causality algorithm Hy's Law is a clinical and regulatory safety concept, whereas eDISH is a graphical method for identifying subjects for evaluation eDISH is more definitive than medical review in determining Hy's Law cases Hy's Law applies only to placebo subjects, while eDISH applies only to treated subjects

Question 10 of 10 What does improvement after discontinuation of treatment generally contribute to a causality assessment?

It can support causality but is not conclusive by itself It proves the investigational product caused the injury It excludes all alternative causes It is irrelevant because only baseline values matter

QPPV.com

eDISH: Evaluating Drug-Induced Serious Hepatotoxicity in Clinical Trials

Cookie Settings